Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.
Sara RedenšekDušan FlisarMaja KojovićMilica Gregorič KrambergerDejan GeorgievZvezdan PirtošekMaja TroštVita DolzanPublished in: Journal of neuroinflammation (2019)
Apart from some nominally significant associations, one significant association between CAT genetic variability and peripheral edema was observed as well. Therefore, the results of our study suggest some links between genetic variability in inflammation- and oxidative stress-related pathways and non-motor adverse events of dopaminergic treatment. However, the investigated polymorphisms do not play a major role in the occurrence of the disease and the adverse events of dopaminergic treatment.